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HypoxemiaAbstract Hepcidin has a regulatory role in inﬂammation, the immune system, and iron metabo-
lism. It has been shown that proinﬂammatory cytokine interleukin 6 (IL-6) is an important inducer
of hepcidin synthesis during infection and inﬂammation.
Aim of the work: To study the relationship between serum hepcidin level and hypoxemia in the
COPD patients and its relation to COPD severity.
Patients and methods: A prospective case control study to compare serum hepcidin levels and
other parameters in 70COPDpatients treated at the PulmonologyDepartment, King FahadHospital
Dammam, with 34 age and sex matched healthy controls. All subjects participating in the study
underwent a complete physical examination and detailed pulmonary function tests (PFTs). A sample
from the radial artery for arterial blood gas analysis was done. As well as a panel of other tests includ-
ing hemoglobin, hematocrit (hct), Iron, CRP, ferritin and total iron binding capacity. A hepcidin
prohormone enzyme immunoassay kit (RE 54051, IBL) was used for serum hepcidin measurement.
Results: COPD patients had signiﬁcantly lower serum hepcidin level compared to the control
group (204.60 ± 53.12 and 280.81 ± 50.61, respectively). Furthermore there was a signiﬁcantly
greater reduction in serum hepcidin level in patients with severe COPD compared to patients with
mild COPD. A positive correlation was found between serum hepcidin levels and arterial oxygen sat-
uration (SaO2,%) and FEV1 level (P= 0.005). There was a negative correlation between serum hep-
cidin level and the ages of patients and packs of cigarettes consumed per year (P= 0.003).
Conclusion: Our study demonstrated a signiﬁcant reduction in serum hepcidin levels in COPD
patients, and the degree of reduction correlated with the severity of COPD and hypoxemia.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a major
public health problem. It is the fourth leading cause of chronic
morbidity and mortality in the United States, and is projectedd.
58 A. Attia et al.to rank ﬁfth in 2020 in burden of disease caused worldwide,
according to a study published by the World Health Organiza-
tion [1]. Local and systemic inﬂammation, together with arterial
hypoxemia and oxygen delivery to tissue, are known to inﬂuence
the prognosis of COPD [2]. In many chronic inﬂammatory dis-
eases, changes occur in ironmetabolism.Hepcidin, a recently dis-
covered hormone responsible for regulating iron homeostasis, is
becoming increasingly important as a possible inﬂammatory
marker. Hepcidin is a peptide hormone produced primarily by
the liver and secreted into the circulation. Its synthesis increases
in response to iron and inﬂammation and decreases in response
to erythropoiesis. Hepcidin regulates systemic iron metabolism
by interacting with its receptor ferroportin, a transmembrane
iron export protein. Ferroportin is abundantly expressed on the
cell surface of reticuloendothelial [3] macrophages (i.e., resident
macrophages of the liver, spleen, and bone marrow) and on the
basolateral membrane of duodenal enterocytes. These 2 macro-
phages of the liver, spleen, and bone marrow and on the basolat-
eral membrane of duodenal enterocytes. Hepcidin inhibits iron
release at both of these sites by binding to cell surface ferroportin
and causing its internalization and subsequent degradation.Hep-
cidin can therefore be considered as a negative regulator of iron
absorption and recycling. Hepcidin (hepatic bactericidal protein)
discovered by Park et al. [4] is synthesized in the liver, has a role in
iron metabolism, and is coded by human hepcidin gene (HAMP;
OMIM 606464) located on chromosome 19q13.1 [5,6]. Nemeth
et al. [7] have shown that the cytokine interleukin (IL)-6 is neces-
sary and sufﬁcient for the induction of hepcidin during inﬂamma-
tion, establishing that the iron regulatory peptide plays a key role
in the anemia of chronic diseases. Induction by IL-6 involves sig-
nal transduction by JAKkinase regulation of Signal Activator of
Transcription [8,9], adding to the complexity of transcriptional
responses dictating hepcidin regulation [10,11]. Although pro-
duction by the liver most likely accounts for the majority of hep-
cidin in the systemic circulation the regulatory peptide can be
synthesized in other tissues including heart [12,13], kidney [14],
adipose tissue [15], spinal cord [16], myeloid cells [17], splenic
and alveolar macrophages [18], and monocytes [19].
Aim of the work
To study the relationship between serum hepcidin level and
hypoxemia in the COPD patients and its relation to COPD
severity.
Patients and methods
The study was approved by the King Fahad Hospital Ethics
and Research committee. All patients and control subjects
gave their written informed consents before participating in
the study. The current study included 2 groups: Group I: 70
COPD patients aged (mean ± SD) 63.18 ± 7.19 years,
between January 2013 and August 2014, and who were in sta-
ble condition were included in this study, which was seen at the
Pulmonology Department of King Fahad Hospital Dammam,
Kingdom of Saudi Arabia, and Group II: 34 age and sex
matched randomly selected control subjects with no pulmon-
ary disease aged (mean ± SD) 62.6 ± 6.1 years. The patients
were divided according to the GOLD criteria as follows: Mild
COPD (n:20), Moderate COPD (n:32), and Severe COPD
(n:18). The severity of the COPD was categorized into mild(forced expiratory volume in one second/forced vital capacity
[FEV1/FVC < 0.70, FEV1P 80% predicted), moderate
(FEV1/FVC < 0.70, 50% 6 FEV1 < 80% predicted), and
severe (FEV1/FVC < 0.70, 30% 6 FEV1 < 50% predicted).
The treatment of our patient’s protocols was explained to
GOLD criteria [20]. All the patient group and the control
group included in the study had C-reactive protein (CRP) lev-
els within the normal limits (upper normal level, 10 mg/l). Ane-
mia was deﬁned as Hb < 12 g/dl. Baseline arterial oxygen
saturation was deﬁned 688%. The study included patients
with COPD over 40 years of age, having a diagnosis of COPD
according to the GOLD 2009 [20], being at a stable phase of
COPD.
Exclusion criteria
Exclusion criteria were acute COPD exacerbations in the last
3 months (increased cough, dyspnea, sputum production,
and/or purulence) [20], other infections, a blood transfusion
in the last 6 months, anti inﬂammatory therapy (oral, paren-
teral systemic glucocorticosteroids) within the last 3 months,
and anemia within the last 6 months. Demographic informa-
tion and smoking history of patients were recorded. Body mass
indexes (BMI; kg/m2) were calculated for all groups. Respira-
tory function tests were performed in all patients at the respi-
ration laboratory of our clinic using a Jaeger spirometer
according to Thoracic Society (ATS) guidelines [21] using
Vmax29 Sensor Medics (VIASYS). FEV1, FVC, and FEV1/
FVC (Tiffeneau index) parameters were measured at least
three times and the values were recorded. The lung graphs of
the patients were evaluated. The patient group and the control
group also underwent physical examinations.
In all patient group and the control group included in the
study, blood and serum samples for full blood testing were
taken in the morning on an empty stomach. Serum iron, total
iron binding capacity, ferritin, hemoglobin, and hematocrit
(hct) levels were assessed using standard laboratory methods.
Serum samples for hepcidin were centrifuged for 10 min at
3000 rpm and stored at 20 C. A hepcidin prohormone
enzyme immunoassay kit (RE 54051, IBL) was used for serum
hepcidin measurement. Also, a sample from the radial artery
for arterial blood gas analysis was obtained.The statistical analysis
Comparison among the groups was conducted using Student’s
t-test for normally distributed variables. The nonparametric
Mann–Whitney U test was used for variables with a non-
Gaussian distribution. Normally distributed variables were
expressed as mean ± SD. For correlation studies, the Pearson
correlation test was used. A P value of <0.05 was considered
statistically signiﬁcant. The commercial statistical software
package used was SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
The relationship of hepcidin levels with other variables was
examined using the Spearman Correlation coefﬁcient.Results
Demographic information and laboratory results of the COPD
patients group and the control group are shown in Table 1.
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was higher than the COPD patient group with signiﬁcant
difference (280.81 ± 50.61 and 204.60 ± 53.12), respectively
(P< 0.001). Among the COPD patient group, the hepcidin
level in the mild COPD patient group had the highest mean
level (259.72 ± 49.81 ng/ml), and the severe COPD patient
group had the lowest mean hepcidin level (149.33 ± 31.74 ng/
ml). The mean level in the moderate COPD patient group
was found to be (201.25 ± 24.9 ng/ml). The mean level in the
control group was 280.81 ng/ml. The serum hepcidin level in
the mild COPD patient group was higher than the moderate
and severe COPD patients. There was no difference in terms
of hepcidin levels between the moderate and severe COPD
patient groups (P= 0.624) and there was difference in hepcidin
levels between mild and severe COPD patients group
(P= 0.003) are shown in Table 2. Each COPD patient group
was compared with the normal group. There was no difference
between the healthy control group and the mild COPD patient
group (P= 0.781), whereas there was a difference between the
control group and the moderate (P= 0.004) and severe
(P= 0.002) COPD patient groups. The hepcidin level of the
control group was higher than the moderate and severe COPD
patient groups. Fig. 1 shows the serum hepcidin levels in COPD
patients and control group. Serum hepcidin levels were lower in
COPD patients than the control group, and decreased by sever-
ity of COPD. There was a positive correlation between serum
hepcidin level and hct (r= 0.53, P= 0.006), iron (r= 0.69,
P= 0.000), ferritin (r= 0.48, P= 0.001), PaO2 (r= 0.67,
P= 0.000), SaO2 (r= 0.51, P= 0.001) Fig. 2, and FEV1 level
(r= 0.51, P= 0.009). There was a negative correlation
between serum hepcidin level and the ages of patients
(r= 0.63, P= 0.002), packs of cigarettes consumed per year
(r= 0.45, P= 0.003).
Discussion
In our study, serum hepcidin levels were signiﬁcantly different
between the healthy control group and the COPD patient
group (P= 0.004), serum hepcidin levels were signiﬁcantly dif-
ferent between the healthy control group and the moderate
COPD patients (P= 0.004), between the healthy control
group and the severe (P= 0.002) COPD patients, between
the mild and moderate COPD patients (P= 0.001), and
between the mild and severe COPD (P= 0.003) patientsTable 1 Demographic and laboratory characteristics of the COPD
Control
Age (year) 62.6 ±
BMI (kg/m2) 25.21 ±
Cigarette (package/year) –
Hemoglobin (12–16 g/dl) 14.7 ±
Iron (Fe) (50–170 g/dl) 83.2 ±
Ferritin (18–250 ng/dl) 89.72 ±
TIBC (228–428 g/dl) 301 ±
SaO2 (%) 97.16 ±
PaO2 (mmHg) 95.88 ±
PaCO2 (mmHg) 41.24 ±
FEV1% of predicted 90.85 ±
Hepcidin (ng/ml) 280.81 ±
BMI = body mass index; TIBC = total iron binding capacity, PaO2 =
dioxide pressure; SaO2 = arterial oxygen saturation.group. No relationship was found between Serum hepcidin lev-
els in the healthy control group and the mild COPD patients
(P= 0.541). These ﬁndings suggest that hepcidin could be
an important marker which could be used to evaluate the dis-
ease state. In COPD patients, tissue hypoxia occurs when the
partial oxygen pressure (PaO2) falls below 60 mmHg which
causes systemic effects. Serious complications may occur when
vital organs cannot receive sufﬁcient oxygen. Hypoxemia is
seen more in the severe COPD patient group than in the mild
and moderate COPD patient groups. Systemic hypoxia
reduced hepcidin production in the liver. However, the molec-
ular mechanisms in which hypoxemia plays a role to repress
hepcidin production has not yet been fully understood [22].
In our severe COPD patient group, there was a positive corre-
lation between serum hepcidin levels and PaO2 (P= 0.000).
This result demonstrates that there is a correlation between
the degree of hypoxemia and the serum hepcidin level in the
severe COPD patient group. The serum level of hepcidin that
increases with inﬂammation and decreases with hypoxia and
anemia. Hepcidin is a liver produced peptide implicated in
the anemia of inﬂammation [23]. Inﬂammation increases hep-
cidin expression. Also, serum hepcidin was abnormally
increased in patients with inﬂammation (CRP > 10 mg/L),
in patients with multiple myeloma [24,25] and in patients with
chronic kidney disease [26] without associated inﬂammatory
disorders. In a study, it was found that hepcidin was expressed
by airway epithelial cells and was induced by both interferon
gamma and IL-6 in a cell-speciﬁc pattern and may serve as a
protective factor through its direct antimicrobial effects [27].
Our patient group and the control group had no anemia and
high serum CRP levels. Hepcidin plays a crucial role in the
anemia of chronic disease. We think that in our severe COPD
patient group, the decrease in serum hepcidin levels is related
to hypoxemia rather than inﬂammation. In another study it
was shown that hepcidin is also produced in mouse macro-
phages infected with intracellular Mycobacteria [28]. However,
there are conﬂicting ﬁndings about the serum hepcidin level
related to acute and chronic inﬂammation in the literature.
In a previous study, the pro-hepcidin concentration was signif-
icantly higher in the patients with active rheumatoid arthritis
(RA) than those with inactive to moderate RA [29].
Our results showed that the serum hepcidin level increased
with increasing hct (P= 0.009) and serum iron (P= 0.000)
levels in the severe COPD patient group. Hepcidin productionpatient groups and the control group.
(n:34) COPD patients (n:70)
6.1 63.18 ± 7.19
3.41 23.81 ± 5.12
36.20 ± 3.15
2.09 15.4 ± 1.99
6.03 83.96 ± 4.92
13.6 90.25 ± 11.3
26.4 298.97 ± 30.12
2.56 93.54 ± 3.89
1.5 69.8 ± 14.23
3.1 60.28 ± 10.32
3.9 65.33 ± 12.8
50.61 204.60 ± 53.12
partial arterial oxygen pressure; PaCO2 = partial arterial carbon
Table 2 Serum hepcidin level among COPD patients.
COPD patients
Mild (n:20) Moderate (n:32) Severe (n:18)
Hepcidin (ng/ml) 259.72 ± 49.81 201.25 ± 24.9 149.33 ± 31.74
Figure 1 Serum hepcidin level among COPD patients and the
control group.
Figure 2 Positive correlation between the serum hepcidin level
and SO2.
60 A. Attia et al.also correlated with the serum ferritin level. It was found that
the serum hepcidin level increased when the serum ferritin level
increased in the severe COPD patient group. In our study, no
relationship was found between BMI and serum hepcidin lev-
els in the moderate and severe COPD patient groups. Only a
positive correlation was found between hepcidin levels and
BMI (P= 0.01) in the mild COPD patient group. Impaired
pulmonary function is a strong risk factor for the development
of COPD and a marker of disease severity. BMI has a negative
effect on the quality of life of patients with COPD, and previ-
ous studies have found a relationship between poor prognosis,
mortality, and BMI [30,31]. A number of studies have found a
relationship between low serum hepcidin levels and BMI
[32,33]. Also, the correlation between serum hepcidin levels
and BMI was shown in some studies on obesity [34]. All of
our patients had normal or low BMI. In our study, serumhepcidin levels decreased with aging (P= 0.002). However,
this relation may come from multifactorial reasons and more
likely to be related to hepatic function, a decrease in lung
and chest wall compliance, an increase in prevalence of a ven-
tilation–perfusion disorder, low arterial oxygen pressure, and
an increase in physical dead space make hypoxemia more
apparent. The hepatic synthesis of hepcidin increases when
the serum iron concentration goes up. In contrast, hepcidin
synthesis decreases when there is iron deﬁciency.
Conclusion
Our study demonstrated a signiﬁcant reduction in serum hep-
cidin levels in COPD patients, and the degree of reduction cor-
related with the severity of COPD and hypoxemia.
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